Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immunocore Holdings (IMCR) Non Operating Income (2023 - 2025)

Immunocore Holdings' Non Operating Income history spans 3 years, with the latest figure at $4.5 million for Q4 2025.

  • For Q4 2025, Non Operating Income rose 353.58% year-over-year to $4.5 million; the TTM value through Dec 2025 reached $19.7 million, up 38.95%, while the annual FY2025 figure was $19.7 million, 38.95% up from the prior year.
  • Non Operating Income for Q4 2025 was $4.5 million at Immunocore Holdings, down from $5.1 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $9.0 million in Q3 2024 and bottomed at -$325000.0 in Q1 2023.
  • The 3-year median for Non Operating Income is $2.7 million (2024), against an average of $2.8 million.
  • The largest annual shift saw Non Operating Income surged 4767.71% in 2024 before it crashed 43.52% in 2025.
  • A 3-year view of Non Operating Income shows it stood at -$190000.0 in 2023, then skyrocketed by 622.63% to $993000.0 in 2024, then soared by 353.58% to $4.5 million in 2025.
  • Per Business Quant, the three most recent readings for IMCR's Non Operating Income are $4.5 million (Q4 2025), $5.1 million (Q3 2025), and $4.7 million (Q2 2025).